company background image
BGD logo

Biogened WSE:BGD Stock Report

Last Price

zł23.40

Market Cap

zł57.5m

7D

-10.0%

1Y

32.2%

Updated

18 Nov, 2024

Data

Company Financials

Biogened S.A.

WSE:BGD Stock Report

Market Cap: zł57.5m

BGD Stock Overview

Develops, produces, and distributes pharmaceutical products in Poland. More details

BGD fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance5/6
Financial Health4/6
Dividends2/6

Rewards

Trading at 79% below our estimate of its fair value

Earnings grew by 53% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the Polish market

Has a high level of debt

Does not have a meaningful market cap (PLN57M)


Biogened S.A. Competitors

Genomed Spólka Akcyjna

WSE:GEN

zł35.9m

Mabion

WSE:MAB

zł174.2m

Ambee Pharmaceuticals

DSE:AMBEEPHA

৳1.7b

Arab Drug

CASE:ADCI

ج.م619.3m

Price History & Performance

Summary of all time highs, changes and price drops for Biogened
Historical stock prices
Current Share Pricezł23.40
52 Week Highzł32.60
52 Week Lowzł16.20
Beta0.70
11 Month Change5.41%
3 Month Change1.74%
1 Year Change32.20%
33 Year Change165.91%
5 Year Change214.09%
Change since IPO-41.50%

Recent News & Updates

Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Nov 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Aug 28
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Recent updates

Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

Nov 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt

A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Aug 28
A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb

Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Aug 22
Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)

Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

May 23
Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding

Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

May 09
Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden

Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Feb 21
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations

Is Biogened (WSE:BGD) A Risky Investment?

Feb 01
Is Biogened (WSE:BGD) A Risky Investment?

Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

Feb 01
Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump

We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Jun 30
We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Oct 08
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

Mar 25
Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Dec 09
These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well

Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Jul 29
Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet

Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Apr 30
Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly

Is Biogened (WSE:BGD) A Risky Investment?

Jan 24
Is Biogened (WSE:BGD) A Risky Investment?

Shareholder Returns

BGDPL PharmaceuticalsPL Market
7D-10.0%-5.4%-3.3%
1Y32.2%40.0%1.1%

Return vs Industry: BGD underperformed the Polish Pharmaceuticals industry which returned 40% over the past year.

Return vs Market: BGD exceeded the Polish Market which returned 1.1% over the past year.

Price Volatility

Is BGD's price volatile compared to industry and market?
BGD volatility
BGD Average Weekly Movement9.0%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement4.8%
10% most volatile stocks in PL Market8.6%
10% least volatile stocks in PL Market3.0%

Stable Share Price: BGD's share price has been volatile over the past 3 months compared to the Polish market.

Volatility Over Time: BGD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
2007218Andrzej Grzegorzewskiwww.biogened.pl

Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland. The company offers dermo-cosmetics under the Dermedic brand; and thermal water. It also exports its products.

Biogened S.A. Fundamentals Summary

How do Biogened's earnings and revenue compare to its market cap?
BGD fundamental statistics
Market capzł57.48m
Earnings (TTM)zł5.36m
Revenue (TTM)zł105.76m

10.7x

P/E Ratio

0.5x

P/S Ratio

Is BGD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BGD income statement (TTM)
Revenuezł105.76m
Cost of Revenuezł32.88m
Gross Profitzł72.88m
Other Expenseszł67.53m
Earningszł5.36m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)2.18
Gross Margin68.91%
Net Profit Margin5.07%
Debt/Equity Ratio54.3%

How did BGD perform over the long term?

See historical performance and comparison

Dividends

2.1%

Current Dividend Yield

23%

Payout Ratio

Does BGD pay a reliable dividends?

See BGD dividend history and benchmarks
When do you need to buy BGD by to receive an upcoming dividend?
Biogened dividend dates
Ex Dividend DateSep 12 2024
Dividend Pay DateNov 18 2024
Days until Ex dividend68 days
Days until Dividend pay date1 day

Does BGD pay a reliable dividends?

See BGD dividend history and benchmarks